News & Updates

A first-in-human randomized, phase I study has provided evidence to support the clinical development of RG6346 as a therapeutic regimen for chronic hepatitis B virus (HBV) infection (CHB), with the goal of sustained hepatitis B surface antigen (HBsAg) loss in CHB patients.

Treatment with antiviral therapy is beneficial and generally tolerated in children with chronic hepatitis B virus (HBV) infection in the immune-tolerant stage, according to the results of a systematic review and meta-analysis.

Patients with type 2 diabetes (T2D) who received canagliflozin benefit from improved liver biochemistry and metabolism, a recent study has shown. In addition, treatment with canagliflozin appears to confer positive effects on liver fibrosis.

Treatment with the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide results in a greater decrease in liver fat content (LFC) relative to the GLP-1 receptor agonist semaglutide in patients with nonalcoholic fatty liver disease (NAFLD), results of a phase IIa trial have shown.

Treatment outcomes with nucleos(t)ide analogues for hepatitis B patients appear to differ by sex, such that men are more likely to have biochemical response and achieve clinical remission than women, a study has shown.